The global chlamydia diagnostics market garnered a market value of US$ 1.17 Billion in 2022 and is expected to accumulate a market value of US$ 3.69 Billion by registering a CAGR of 11% in the forecast period 2023 to 2033. Growth of the chlamydia diagnostics market can be attributed to increasing awareness, technological advancements, and growing demand for early disease diagnosis. the market for chlamydia diagnostics registered a CAGR of 8% in the historical period 2018 to 2022
Chlamydia diagnostics refer to the tests and procedures used to identify the presence of Chlamydia trachomatis bacteria in a person's body. Chlamydia is a sexually transmitted infection (STI) that can be asymptomatic, meaning a person may not show any symptoms but still be infected. Therefore, diagnosing chlamydia is important to prevent the spread of the infection and to start treatment early.
The most common diagnostic method for chlamydia is a nucleic acid amplification test (NAAT), which detects the genetic material of the Chlamydia trachomatis bacteria. This test can be performed on a urine sample or a swab taken from the genital area. Other diagnostic methods may include culture tests or antigen tests, but these are less commonly used.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 1.30 Billion |
| Anticipated Forecast Value (2033) | US$ 3.69 Billion |
| Projected Growth Rate (2023 to 2033) | 11% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Chlamydia diagnostics reflected a value of 8% during the historical period, 2018 to 2022.
The growth in the market was primarily driven by factors such as the increasing prevalence of chlamydia infections, growing awareness and initiatives for early disease diagnosis, and technological advancements in diagnostic testing.
Furthermore, North America held the largest share of the chlamydia diagnostics market in 2018, followed by Europe and Asia-Pacific. The high prevalence of sexually transmitted infections (STIs) in North America, coupled with the presence of advanced healthcare infrastructure, is expected to drive the growth of the chlamydia diagnostics market in the region.
Thus, the market for Chlamydia diagnostics is expected to register a CAGR of 11% in the forecast period 2023 to 2033.
Increasing prevalence of chlamydia infections favoring market growth
Chlamydia is one of the most common sexually transmitted infections (STIs) worldwide, with an estimated 131 Billion new cases each year. The growing prevalence of chlamydia infections is driving the demand for diagnostic tests to identify the infection early.
Increased awareness about the importance of early diagnosis and treatment of STIs is driving the demand for diagnostic tests, including those for chlamydia. Additionally, government and non-governmental organizations are implementing various initiatives to increase awareness about STIs and promote early disease diagnosis.
The development of new and advanced diagnostic tests for chlamydia, such as nucleic acid amplification tests (NAATs), has improved the accuracy and reliability of chlamydia diagnostics. Additionally, point-of-care testing (POCT) for chlamydia is becoming increasingly popular due to its ease of use and rapid results.
The availability of home testing kits for chlamydia is increasing, which is driving the demand for chlamydia diagnostics. Home testing kits are convenient and offer privacy to patients, which is particularly important for STI testing.
Personalized medicine, which involves tailoring medical treatment to an individual's specific needs, is becoming increasingly popular. Diagnostic tests, including those for chlamydia, are an important tool in personalized medicine, allowing healthcare providers to identify the infection early and tailor treatment to the individual.
Availability of diagnostics tools shaping the landscape for chlamydia diagnostics market
Nucleic acid amplification tests (NAATs): NAATs are the most accurate and sensitive tests for chlamydia diagnostics. These tests detect the genetic material (DNA or RNA) of the Chlamydia trachomatis bacteria in a patient's urine or swab sample.
Enzyme-linked immunosorbent assay (ELISA): ELISA is a type of blood test that detects the presence of antibodies against the Chlamydia trachomatis bacteria in a patient's blood.
Direct fluorescent antibody (DFA) test: DFA is a laboratory test that involves staining the Chlamydia trachomatis bacteria with fluorescent dyes, making them visible under a microscope.
Nucleic acid hybridization tests: These tests detect the presence of the Chlamydia trachomatis bacteria by using probes that bind to specific DNA or RNA sequences of the bacteria.
Culture tests: Culture tests involve growing the Chlamydia trachomatis bacteria in a laboratory culture, which can take several days. This test is less commonly used due to its lower sensitivity and longer turnaround time.
Point-of-care tests (POCTs): POCTs are rapid diagnostic tests that can provide results within minutes. These tests can be performed in a clinic or doctor's office and are usually based on antigen detection or NAAT technology.
Principal Consultant
Lack of awareness about STIs along with cost of diagnostic tests derailing market growth of chlamydia diagnostics market
There is still a lack of awareness among the general population about sexually transmitted infections (STIs) such as chlamydia, which leads to underdiagnosis and undertreatment of the infection. Limited access to healthcare services, particularly in developing countries, can hinder the growth of the chlamydia diagnostics market. This can limit the availability of diagnostic tests and prevent patients from receiving appropriate treatment.
The cost of diagnostic tests for chlamydia can be a barrier for some patients, particularly in low-income settings. This can lead to delayed diagnosis and treatment of the infection, which can have serious health consequences. The stigma associated with STIs can prevent some individuals from seeking testing and treatment. This can further contribute to the underdiagnosis and undertreatment of chlamydia.
The emergence of antibiotic-resistant strains of Chlamydia trachomatis is a growing concern, as this can limit the effectiveness of antibiotics in treating the infection. Currently, there are no effective vaccines against chlamydia. The lack of a vaccine hinders efforts to prevent the spread of the infection and reduces the focus on the development of diagnostic tests.
Inclination towards early diagnosis creating lucrative opportunities of chlamydia diagnostics market
The North America chlamydia diagnostics market is a significant segment of the global chlamydia diagnostics market. North America includes countries such as the United States and Canada, and it is considered one of the leading markets for chlamydia diagnostics.
Factors driving the growth of the North America chlamydia diagnostics market include the increasing prevalence of chlamydia infections, growing awareness about STIs and the importance of early diagnosis, and the availability of advanced diagnostic technologies.
The United States is the largest market for chlamydia diagnostics in North America. The growth is attributed to factors such as the high prevalence of chlamydia infections in the country, the availability of advanced diagnostic technologies, and the presence of major market players. Thus, North America is expected to possess 48% market share for chlamydia market share in 2023.
Development of advanced diagnostic technologies bolstering market growth of chlamydia diagnostics in Europe
Chlamydia is one of the most commonly reported sexually transmitted infections in Europe. The increasing prevalence of chlamydia is driving the demand for chlamydia diagnostic tests in the region. The increasing awareness about sexually transmitted infections, including chlamydia, is leading to more individuals seeking testing and treatment. This is driving the growth of the chlamydia diagnostics market in Europe.
The development of advanced diagnostic technologies, such as molecular diagnostics tests, has led to the development of more accurate and sensitive chlamydia diagnostic tests. This is also driving the growth of the market. The increasing healthcare expenditure in Europe is leading to more investments in healthcare infrastructure, including diagnostic facilities. This is driving the growth of the chlamydia diagnostics market as more individuals have access to testing and treatment.
Point-of-care testing for chlamydia is becoming increasingly popular due to its rapid and easy-to-use nature. This is driving the growth of the point-of-care testing segment in the market. Thus, Europe is expected to possess 46% market share for chlamydia market share in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Faster results making NAAT a likeable choice for chlamydia diagnostics
There are several types of tests available for the diagnosis of chlamydia, including nucleic acid amplification tests (NAATs), enzyme immunoassays (EIAs), direct fluorescent antibody (DFA) tests, and culture tests.
In recent years, nucleic acid amplification tests (NAATs) have become the most popular type of test for chlamydia diagnostics. NAATs have a high sensitivity and specificity for chlamydia and can detect the presence of the bacterial DNA in a patient's urine, swab, or blood sample. They are also considered to be more reliable than other types of tests, such as culture tests, which can be time-consuming and have a lower sensitivity.
Furthermore, NAATs can be performed using various types of samples, such as urine, vaginal swabs, and rectal swabs, making them a convenient and non-invasive option for patients. Additionally, some NAATs can provide results within a few hours, which is much faster than traditional culture tests that can take several days to yield results. Overall, due to their high accuracy, ease of use, and rapid results, NAATs have become the most popular type of test for chlamydia diagnostics in recent years. Thus, by test type, NAATs are expected to possess 49% market share for chlamydia market share in 2023.
Key players in the chlamydia diagnostics market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Hologic, Inc., Quidel Corporation, DiaSorin SpA Becton, Dickinson and Company, Bio-Rad Laboratories, Pfizer, Inc., AstraZeneca and Teva Pharmaceuticals
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 1.30 Billion |
| Market Value in 2033 | US$ 3.69 Billion |
| Growth Rate | CAGR of 11% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The market is expected to reach US$ 1.30 billion in 2023.
Development of rapid and point-of-care tests and the use of molecular diagnostic techniques for accuracy.
The market is likely to record a growth of 11% from 2023 to 2033.
Nucleic acid amplification tests (NAATs) and rapid antigen tests are leading methods.
North America is the leading marker for chlamydia diagnostics.
1. Executive Summary | Chlamydia Diagnostics Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Test Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Test Type, 2023 to 2033 5.3.1. Culture Tests 5.3.2. Nucleic Acid Amplification Tests (NAAT) 5.3.3. Direct Fluorescent Antibody Tests 5.3.4. Serology Tests 5.4. Y-o-Y Growth Trend Analysis By Test Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Test Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-User 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By End-User, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-User, 2023 to 2033 6.3.1. Hospitals 6.3.2. Clinics 6.3.3. Diagnostic Centres 6.4. Y-o-Y Growth Trend Analysis By End-User, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By End-User, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. South Asia 7.3.5. East Asia 7.3.6. Oceania 7.3.7. MEA 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. USA 8.2.1.2. Canada 8.2.2. By Test Type 8.2.3. By End-User 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Test Type 8.3.3. By End-User 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Test Type 9.2.3. By End-User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Test Type 9.3.3. By End-User 9.4. Key Takeaways 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. United kingdom 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Test Type 10.2.3. By End-User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Test Type 10.3.3. By End-User 10.4. Key Takeaways 11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. India 11.2.1.2. Malaysia 11.2.1.3. Singapore 11.2.1.4. Thailand 11.2.1.5. Rest of South Asia 11.2.2. By Test Type 11.2.3. By End-User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Test Type 11.3.3. By End-User 11.4. Key Takeaways 12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Test Type 12.2.3. By End-User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Test Type 12.3.3. By End-User 12.4. Key Takeaways 13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Australia 13.2.1.2. New Zealand 13.2.2. By Test Type 13.2.3. By End-User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Test Type 13.3.3. By End-User 13.4. Key Takeaways 14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Test Type 14.2.3. By End-User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Test Type 14.3.3. By End-User 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. USA 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Test Type 15.1.2.2. By End-User 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Test Type 15.2.2.2. By End-User 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Test Type 15.3.2.2. By End-User 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Test Type 15.4.2.2. By End-User 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Test Type 15.5.2.2. By End-User 15.6. United kingdom 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Test Type 15.6.2.2. By End-User 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Test Type 15.7.2.2. By End-User 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Test Type 15.8.2.2. By End-User 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Test Type 15.9.2.2. By End-User 15.10. India 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Test Type 15.10.2.2. By End-User 15.11. Malaysia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Test Type 15.11.2.2. By End-User 15.12. Singapore 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Test Type 15.12.2.2. By End-User 15.13. Thailand 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Test Type 15.13.2.2. By End-User 15.14. China 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Test Type 15.14.2.2. By End-User 15.15. Japan 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Test Type 15.15.2.2. By End-User 15.16. South Korea 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Test Type 15.16.2.2. By End-User 15.17. Australia 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Test Type 15.17.2.2. By End-User 15.18. New Zealand 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Test Type 15.18.2.2. By End-User 15.19. GCC Countries 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Test Type 15.19.2.2. By End-User 15.20. South Africa 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Test Type 15.20.2.2. By End-User 15.21. Israel 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Test Type 15.21.2.2. By End-User 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Test Type 16.3.3. By End-User 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Abbott Laboratories 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. F. Hoffmann-La Roche Ltd 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. Hologic, Inc. 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Quidel Corporation 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. DiaSorin SpA 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. Becton, Dickinson and Company 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Bio-Rad Laboratories 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Pfizer, Inc. 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. AstraZeneca 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. Teva Pharmaceuticals 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Chlamydia Diagnostics Market
